Welcome to our dedicated page for HERON THERAPEUTICS /DE/ SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HERON THERAPEUTICS /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HERON THERAPEUTICS /DE/'s regulatory disclosures and financial reporting.
Heron Therapeutics, Inc. entered into Amendment No. 1 to its Tax Benefit Preservation Plan with Computershare Trust Company, N.A. as rights agent. The amendment changes the Plan’s definition of “Final Expiration Date,” extending all prior references to August 14, 2026 to now mean August 14, 2029. This effectively prolongs the duration of the Tax Benefit Preservation Plan by three years. The change is described as a material definitive agreement and as a material modification to the rights of security holders, with the full amendment filed as Exhibit 4.1 and incorporated by reference.
Heron Therapeutics, Inc. reported insider equity activity by Chief Operating Officer Mark Earl Hensley on August 6, 2026. He exercised 31,250 Restricted Stock Units, receiving an equivalent number of common shares. In a related transaction, 8,888 common shares were delivered or withheld for payment of exercise price or tax liability at $0.5000 per share. Following the transaction, he continued to hold 343,750 Restricted Stock Units representing additional contingent rights to common shares.
Heron Therapeutics reported Q2 2026 net product sales of $37.7M, roughly flat versus $37.2M a year earlier, with CINVANTI remaining the largest contributor. For the first half of 2026, net product sales were $72.4M compared with $76.1M in 2025, reflecting softer oncology product volumes.
The company posted a Q2 2026 net loss of $5.5M and a six‑month net loss of $13.6M, versus a small profit of $0.3M in the prior‑year period, driven largely by higher interest expense of $6.8M year‑to‑date and increased sales and marketing spending. Stockholders’ equity declined to $6.9M from $14.3M at year‑end 2025.
Cash, cash equivalents and short‑term investments totaled $42.7M at June 30, 2026, with net cash used in operations improving to $3.8M in the first half from $19.7M a year earlier. Management, considering a recently amended Working Capital Facility, believes current liquidity will cover at least 12 months of anticipated needs, although tighter covenants, required principal prepayments and a Nasdaq minimum bid‑price deficiency notice highlight ongoing financial risk. The portfolio remains centered on ZYNRELEF, APONVIE, CINVANTI and SUSTOL, with SUSTOL sales scheduled to cease after September 30, 2026 and a recent adverse patent ruling affecting CINVANTI IP.
Heron Therapeutics reported Q2 2026 net revenue of $37.7 million, up 9% from Q1 2026 and roughly flat year-over-year. The company ended June 30, 2026 with $42.7 million in cash, cash equivalents and short-term investments.
Acute Care franchise net revenue grew strongly, rising 43.9% year-over-year in Q2 to $15.3 million, driven by ZYNRELEF ($11.1 million, up 35.0%) and APONVIE ($4.3 million, up 73.6%). Oncology Supportive Care revenue declined 15.9% year-over-year in Q2 to $22.3 million, with CINVANTI down 9.7% and SUSTOL down 77.5%.
Heron posted a Q2 2026 net loss of $5.5 million and a six-month net loss of $13.6 million, versus a small profit a year earlier, while achieving Q2 Adjusted EBITDA of $3.2 million. The company amended its credit facility with Hercules Capital, resetting financial covenants through 2027 and providing for a potential $17.5 million reduction in outstanding principal. Heron withdrew its full-year 2026 guidance for net product sales and Adjusted EBITDA, citing uncertainty following a court decision affecting CINVANTI patents, spending changes, and an ongoing review of strategic alternatives.
Heron Therapeutics (HRTX) Chief Operating Officer Mark Earl Hensley reported the vesting and conversion of 11,769 Restricted Stock Units into 11,769 shares of common stock on July 31, 2026. His direct common stock holdings increased to 148,539 shares, while 164,776 Restricted Stock Units remain outstanding from a 188,315-unit grant dated January 30, 2026, which vests in 16 equal quarterly installments. Each RSU represents a contingent right to receive one share of common stock.
Heron Therapeutics EVP and Chief Development Officer William P. Forbes converted a total of 23,463 restricted stock units into an equal number of common shares on July 30–31, 2026, under time-based vesting schedules. To cover exercise price or tax obligations, 6,674 shares of common stock were withheld at $0.50 per share.
Heron Therapeutics EVP and Chief Financial Officer Ira Duarte reported equity compensation activity involving restricted stock units that settled into common stock on July 30 and 31, 2026. In total, 25,229 RSUs converted into an equal number of common shares, while 7,176 shares were withheld at $0.50 per share in transactions reported under code F for payment of exercise price or tax liability. The RSUs include a 216,562-unit grant awarded on January 30, 2026 that vests in 16 equal quarterly installments beginning one quarter after the grant date, as well as an earlier grant from January 31, 2025 with the same 16-installment vesting structure.
Heron Therapeutics CEO Craig A. Collard exercised previously granted restricted stock units into common stock in late July 2026. On July 30 he converted 50,021 RSUs, and on July 31 he converted 34,789 RSUs, each on a one-for-one basis at a stated price of $0.00 per share. The RSUs vest in 16 equal quarterly installments beginning one quarter after their respective grant dates in January 2025 and January 2026.
Heron Therapeutics, Inc. CEO Craig A. Collard exercised 13,797 restricted stock units into 13,797 shares of common stock on 2026-07-19. After this derivative conversion, he directly holds 771,682 common shares and 82,781 restricted stock units, which vest in 16 equal quarterly installments beginning one quarter after 01/19/2024.
Heron Therapeutics executive William P. Forbes, EVP and Chief Development Officer, reported equity compensation activity on July 19, 2026. He exercised 3874 restricted stock units into common stock, and 1101 shares of common stock were disposed of in a tax-withholding transaction at $0.47 per share. Following these transactions, he directly owned 225485 shares of common stock and held 23246 restricted stock units.